| 2.94 -0.17 (-5.47%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.17 |
1-year : | 4.7 |
| Resists | First : | 3.57 |
Second : | 4.03 |
| Pivot price | 3.28 |
|||
| Supports | First : | 2.82 | Second : | 2.35 |
| MAs | MA(5) : | 2.98 |
MA(20) : | 3.33 |
| MA(100) : | 4.12 |
MA(250) : | 4.85 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 13  |
D(3) : | 8.2 |
| RSI | RSI(14): 33.5 |
|||
| 52-week | High : | 7.98 | Low : | 2.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IVA ] has closed above bottom band by 15.9%. Bollinger Bands are 0.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.13 - 3.15 | 3.15 - 3.16 |
| Low: | 2.87 - 2.88 | 2.88 - 2.9 |
| Close: | 2.91 - 2.94 | 2.94 - 2.97 |
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Wed, 14 Oct 2026
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout - Seeking Alpha
Tue, 13 Oct 2026
Inventiva (NasdaqGM:IVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Fri, 09 Oct 2026
Inventiva (IVA) Short Interest & Short Float | Updated Oct 2026 $IVA - MarketBeat
Sun, 04 Oct 2026
Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth? - Yahoo Finance
Wed, 30 Sep 2026
IVA News | INVENTIVA SA - ADR (NASDAQ:IVA) - ChartMill
Tue, 29 Sep 2026
Inventiva (IVA): H1 Results Put Cash Runway and NATiV3 at the Center of the Story - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 236 (M) |
| Held by Insiders | 1.6557e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 3,680 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4906e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 337.3 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 2.46e+006 % |
| Gross Profit (p.s.) | -76.7 |
| Sales Per Share | -989.05 |
| EBITDA (p.s.) | 1.92e+006 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -17.3 |
| Dividend | 0 |
| Forward Dividend | 8.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|